Skip to main content
. 2015 Oct 7;89(24):12467–12479. doi: 10.1128/JVI.01741-15

TABLE 1.

Resistance profiles of HIV-1 mutants to short-peptide fusion inhibitorsa

HIV-1NL4-3 mutation MTSC22
HP23
SC22EK
IC50 (nM) Fold change IC50 (nM) Fold change IC50 (nM) Fold change
Wild type (WT) 1.86 ± 0.13 1.00 0.41 ± 0.09 1.00 44.13 ± 5 1.00
E49K 73.75 ± 13.53 39.74 5.34 ± 0.18 13.19 1,723.5 ± 184.13 39.06
L57R 746.12 ± 57 402.08 230.05 ± 39.19 567.95 1,714.5 ± 385.06 38.86
N126K 4.27 ± 0.98 2.3 1.37 ± 0.17 3.39 151.93 ± 12.15 3.44
E136G 8.78 ± 1.03 4.73 2.89 ± 0.52 7.14 477.05 ± 42.53 10.81
N163D 2.03 ± 0.3 1.09 0.54 ± 0.05 1.32 46.85 ± 7.84 1.06
E49K/L57R 4,527.86 ± 585.46 2,440.06 1,371.3 ± 561.56 3,385.51 6,694.96 ± 1,036.29 151.73
L57R/N126K 345.2 ± 34.06 186.03 98.64 ± 5.92 243.53 644.12 ± 244.72 14.60
L57R/E136G 1,553.08 ± 535.22 836.96 679.55 ± 191.15 1,677.69 5,322.97 ± 1,529.45 120.63
L57R/N163D 608.95 ± 147.94 328.16 244.95 ± 55.18 604.74 4,014.67 ± 652.8 90.98
E49K/L57R/N126K 1,148.68 ± 145.24 619.02 542.17 ± 141.94 1,338.52 3,226.73 ± 955.88 73.13
E49K/L57R/E136G >7,500 >4041.75 >1,666.67 >4114.73 >7,500 >169.97
E49K/N126K/E136G/N163D (KKGD) 359.22 ± 86.44 193.58 44.26 ± 3.08 109.26 >7,500 >169.97
E49K/L57R/N126K/E136G (KRKG) 2,249.37 ± 655.77 1,212.18 1,389.6 ± 250.15 3,430.69 7,054 ± 617.91 159.86
E49K/L57R/N126K/N163D (KRKD) 5,932.8 ± 331.89 3,197.18 983.12 ± 184.14 2,427.15 5,959.18 ± 447.45 135.05
I37V/E49K/L57R/N126K/N163D (VKRKD) 3,081.67 ± 212.92 1,660.71 1,096.38 ± 444.81 2,706.79 5,649.09 ± 686.21 128.02
E49K/L57R/N126K/E136G/N163D (KRKGD) 3,854.04 ± 533.69 2,076.94 >1,666.67 >4114.73 5,797.24 ± 596.92 131.38
a

Assay was performed in triplicate and repeated three times. Data are expressed as means ± standard deviations. IC50, 50% inhibitory concentration. The change in the IC50 was determined relative to the wild-type level.